These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10852693)

  • 1. Benefits of early utilization of intravenous iron.
    Vogel S
    Nephrol Nurs J; 2000 Feb; 27(1):61-5. PubMed ID: 10852693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron management: innovative solutions to persistent challenges--focus on Ferrlecit.
    Vogel S; Schweitzer S; Seiler S
    ANNA J; 1999 Oct; 26(5):515-21. PubMed ID: 10776080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anemia of chronic renal failure: new treatment alternative.
    Seiler S
    CANNT J; 2000; 10(3):35-9, 43-8; quiz 40-2, 49-51. PubMed ID: 11799582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does iron cause bacterial infections in patients with end stage renal disease?
    Cieri E
    ANNA J; 1999 Dec; 26(6):591-6. PubMed ID: 10876474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
    J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
    Kaskel FJ
    Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
    Silverberg DS; Iaina A; Peer G; Kaplan E; Levi BA; Frank N; Steinbruch S; Blum M
    Am J Kidney Dis; 1996 Feb; 27(2):234-8. PubMed ID: 8659499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease.
    Hutchinson FN; Jones WJ
    Am J Kidney Dis; 1997 May; 29(5):651-7. PubMed ID: 9159297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parenteral iron supplementation in patients with end stage renal disease.
    Vogel SC
    ANNA J; 1998 Dec; 25(6):625-30. PubMed ID: 10188399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing patient concerns about intravenous iron therapy.
    Robbins KC
    Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caring for the renal failure patient: optimizing iron therapy.
    Folkert VW; Javier AM; O'Mara NB
    Nephrol Nurs J; 2002 Dec; 29(6):586-93; quiz 594-5. PubMed ID: 12596608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous iron supplementation in end-stage renal disease patients.
    Matzke GR
    Am J Kidney Dis; 1999 Mar; 33(3):595-7. PubMed ID: 10070926
    [No Abstract]   [Full Text] [Related]  

  • 13. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
    Taylor JE; Peat N; Porter C; Morgan AG
    Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in iron metabolism and erythropoietin requirements after the switch from ferric gluconate to iron saccharose. Is it worth the increased expense?].
    Rodríguez Palomares JR; Fanlo B; Albarracín C; Junquera E
    Nefrologia; 2003; 23(2):181-2. PubMed ID: 12778887
    [No Abstract]   [Full Text] [Related]  

  • 15. Lessons from NKF-DOQI: iron management.
    Van Wyck DB
    Semin Nephrol; 2000 Jul; 20(4):330-4. PubMed ID: 10928334
    [No Abstract]   [Full Text] [Related]  

  • 16. Sodium ferric gluconate complex therapy in anemic children on hemodialysis.
    Warady BA; Zobrist RH; Wu J; Finan E;
    Pediatr Nephrol; 2005 Sep; 20(9):1320-7. PubMed ID: 15971073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical practice guidelines for maintaining adequate iron status with intravenous iron dextran in hemodialysis patients.
    Peacock E; Lindenfeld SM
    ANNA J; 1999 Jun; 26(3):337-43. PubMed ID: 10633605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI.
    Eschbach JW
    Semin Nephrol; 2000 Jul; 20(4):320-9. PubMed ID: 10928333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for optimal iron use for anemia due to chronic kidney disease.
    Hudson JQ; Comstock TJ
    Clin Ther; 2001 Oct; 23(10):1637-71. PubMed ID: 11726002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.